Tanios Bekaii-Saab, MD, Section Chief, Gastrointestinal Oncology, associate professor, Internal Medicine, Pharmacology, The Ohio State University, discusses the results of a phase II study of the oncolytic virus reolysin in the first-line treatment metastatic adenocarcinoma of the pancreas.
The virus did not improve outcomes in the overall population of 73 patients in this study. Some patients may have benefited, Saab says, and researchers are still looking at blood and tissue samples for a potential biomarker. Interestingly, of the patients that crossed over, one patient responded and one had stable disease – this can most likely be attributed to the virus.
<<< View more from the 2014 ESMO Congress